Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Stayble Therapeutics publishes half-year report for 2024

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its half-year report for 2024. The report is available as an attached document and on the Company’s website: https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.Summary   Highlights during the second quarter (April – June 2024) · In April, it was announced that the Company's scientific abstract regarding the treatment concept for herniated discs has been accepted for a poster presentation at the International Society for the Study of the Lumbar Spine (ISSLS)

Neste expands chemical recycling logistics infrastructure at its refinery in Porvoo, Finland

Neste Corporation, News, 20 August 2024 Photo: Installation of new unloading arm for liquefied recycled raw materials at Neste Porvoo refinery harbor, Finland. Source: Neste Neste is expanding its logistics infrastructure for liquefied recycled raw materials at its refinery in Porvoo, Finland, including materials such as liquefied waste plastic and liquefied rubber tires. This lays the foundation to handling larger amounts of liquefied raw materials to support Neste’s strategic aims to advance chemical recycling and transform the Porvoo refinery into a renewable and circular

Transaction in Own Shares

    20 August 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |19/08/2024|+------------------------------------------------------------

STENOCARE updates guidance for 2024

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on August 20, 2024. STENOCARE A/S (“Stenocare” or the “Company”) is updating the guidance from November 06, 2023 based on actual market performance from Q1 and Q2 2024 and the forecast for Q3 and Q4 2024. The guidance of gross sales of 12-18 mDKK is now expected to be 6-8 mDKK for 2024, which is a growth of +7% compared

Changes in Anora Group’s Executive Management Team: The Head of Anora’s Industrial segment to change

Anora Group Plc   Stock exchange release   20 August 2024 at 8.35 a.m. EEST Changes in Anora Group’s Executive Management Team: The Head of Anora’s Industrial segment to change Anora Group’s Senior Vice President, Industrial, Risto Gaggl steps down from his position. He will continue in his current role with Anora until the end of 2024. Anora has appointed Hannu Vähämurto as his successor as of 1 January 2025. Hannu Vähämurto has been with Anora and its predecessor (Altia Oyj) since 2011 in various roles, most recently as Director, Industrial Products since September 2023. Prior to

Anora Group Plc’s Half-year Report January–June 2024: Comparable EBITDA improved in Q2 due to higher gross margin

Anora Group Plc   Half-year Report  20 August 2024 at 8:30 am EEST Anora Group Plc’s Half-year Report January–June 2024: Comparable EBITDA improved in Q2 due to higher gross margin This release is a summary of Anora Group Plc's Half-year Report January-June 2024. The complete report is attached to this release and is also available on the company website at: www.anora.com/en/investors Q2 2024 in brief · Net sales were EUR 177.1 (182.7) million, down by 3.1%. · Comparable EBITDA was EUR 15.2 (13.0) million, or 8.6% (7.1%) of net sales, up by 16.9%. · EBITDA was EUR 14.9 (

Nordhealth AS: Q2 and first half 2024 interim financial report

Please find attached the Q2 presentation and interim financial report of Nordhealth AS first half 2024 results.The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Laine on the 20[th] of August 2024 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/84944459012 The presentation will be recorded and made available on www.nordhealth.com. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Mari Laine, CFO mari.laine@nordhealth.com

Conversion of Scandic’s convertible bonds in an aggregated nominal amount of SEK 383.4 million to shares

In 2021 Scandic Hotels Group AB (publ) (“Scandic”) issued convertible bonds in an aggregated nominal amount of SEK 1,800 million. Convertible bonds in an aggregated nominal amount of SEK 383.4 million have been converted to shares. After the conversion, the aggregated nominal amount for the outstanding convertible bonds amounts to SEK 50 million.Through the conversion, the total number of shares and votes in Scandic increases with 8,841,823 to in total 218,004,846.Through the conversion, the share capital increases with SEK 2,210,455.75 to in total SEK 54,501,211.50. For more

Skanska signs additional contract for data center in Arizona, USA, for USD 153M, about SEK 1.6 billion

Skanska has signed a contract with an existing client to build a data center in Arizona, USA. The contract is worth USD  153M, about SEK 1.6 billion, which will be included in the US order bookings for the third quarter of 2024.The project consists of a single-story data center, totalling approximately 23,200 square meters (250,000 square feet). Work is underway and is scheduled for completion in the fourth quarter of 2025.

JM announces potential lay-offs

In order to adapt the operations to lower production volumes, JM is announcing 145 potential lay-offs within the production organization in Sweden due to redundancy.Despite signs of an improved housing market, it remains cautious. The market situation has led to new housing projects not being able to start at the same pace and with the corresponding number of residential units as in the projects that have been completed. It is therefore necessary to adapt the staffing in the production organization to the redundancy that arises in connection with fewer housing starts. The potential lay-offs

Manufacturing capacity of next generation technology increased to 350 MW p.a. – operational in Q1 2025

HydrogenPro ASA has over a long period of time developed a unique third-generation electrode technology that enables electrolyzers to produce with industry-leading efficiency and reducing the Levelized Cost of Hydrogen. On June 24, 2024 HydrogenPro ASA announced the decision to invest in a new production line for its third-generation electrodes. The production is expected to start Q1 2025 and after optimization work, the production line will reach a capacity of about 350 MW without any additional investment needed (original investment, 70 MNOK). This has been accomplished by optimizing

OssDsign AB (publ) publishes Q2 2024 Interim Report

Reaching milestone in orthobiologics salesOssDsign AB (publ) announces that the interim report for Q2 2024 is now available as a PDF on the company’s website www.ossdsign.com/reports. A PDF version is also attached to this press release.The Q2 2024 results will also be presented at an investor webcast today August 20th at 11:00 CET. The webcast can be accessed via the following link: www.finwire.tv/webcast/ossdsign/q2-2024/ or via the OssDsign website.    The second quarter in figures   · Net sales amounted to TSEK 29,737 (23,997), corresponding to a growth of 143%, or 139%

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

Bergen, Norway, August 20, 2024, – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, to advance the clinical development of BerGenBio’s selective AXL inhibitor bemcentinib in first line (1L) Non-Small Cell Lung Cancer (NSCLC) patients with STK11 mutations (STK11m). BerGenBio’s on-going BGBC016 Phase 1b/2a trial is designed to assess the benefit of

HydrogenPro ASA – Q2 2024 Results

20 August 2024 - HydrogenPro ASA (OSE: HYPRO): HydrogenPro has today reported its financial results for the second quarter. Achievements and highlights: - Decision to invest in third-generation electrode technology with a 350 MW capacity manufacturing facility in Denmark. The investment cost is stipulated to NOK 70 million.  - Awarded DKK 35 million from the Export and Investment Fund of Denmark to continue plans for a large-scale production facility for third-generation electrode technology. - Joint validation program for stack performance and operation conditions for the

Desert Control Releases Q2 2024 Report and Year-to-Date Company Update

Sandnes, Norway, 20 August 2024 — Desert Control AS (DSRT) announces its second-quarter report and interim financial results for the fiscal period ending 30 June 2024. Desert Control made significant progress in the second quarter of 2024. Technological advancements drove a record number of installations and expanded the U.S. project portfolio, while collaboration with partners advanced key regulatory and operational milestones in the Middle East.Operational Highlights: Technological Breakthroughs Drove Record Growth in Installations · Increased Production Capacity: Achieved a

Invitation to the presentation of Bakkafrost's Q2 2024 results 26 August 2024 at 8:00 am (CET)

Bakkafrost's interim report Q2 2024 will be presented at 8:00 am (CET) on 26 August 2024 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway. WEBCAST The presentation will be transmitted live on Bakkafrost's website www.bakkafrost.com. Bakkafrost´s interim report Q2 2024 and associated presentation will be released prior to market opening on 26 August 2024 at 6:00 am (CET). Contacts: · Regin Jacobsen, CEO of P/F Bakkafrost: +298 235001 (mobile) · Høgni Dahl Jakobsen, CFO of P/F Bakkafrost: +298 235060 (mobile) This information is subject of the disclosure

Africa Oil Announces Increase in Its Impact Oil & Gas Shareholding

VANCOUVER, BC, August 19, 2024 /CNW/ -  (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, or the “Company”) is pleased to provide an update on the offer to minority shareholders in Impact Oil & Gas Limited (“Impact”) announced on March 18, 2024 ( “Offer”). The Company made the Offer to acquire shares from minority shareholders in Impact conditional upon completion of the farm down transaction for Impact’s Namibia assets announced on January 10, 2024. The Company has decided to waive this condition and proceed to complete the Offer. Completion is expected to occur

Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.

Genovis, a leading innovator in enzyme technology, today announced the successful divestment of its antibody business to Leinco Technologies Inc., a globally recognized developer of high-quality antibodies for research and diagnostics. This strategic move aligns with Genovis previously communicated focus on optimizing the core business operation and enhancing profitability.The divestment follows a strategic review by Genovis, which identified the need to concentrate on its core enzyme business—a sector where the company has consistently demonstrated market leadership and profitability. The

Bulletin from the annual general meeting in EQL Pharma AB on 19 August 2024

Today, on 19 August 2024, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.Resolution on adoption of accounts and allocation of the company’s result The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and the consolidated balance sheet. The annual general meeting also resolved to distribute the company’s result in accordance with the proposal from the board of directors in the annual report meaning that no dividends are paid for the financial year 2023/2024

Repurchases of shares in Hoist Finance during week 33, 2024

PRESS RELEASEStockholm 19 August 2024   During the period 12 August 2024 – 16 August 2024 Hoist Finance AB (publ) (LEI code: 549300NPK3FB2BEL4D08) (”Hoist Finance”) has repurchased in total 180,000 own shares (ISIN: SE0006887063), as part of the repurchase programme initiated by the Board of Directors. The repurchases form part of the repurchase programme of a maximum of 10 percent of the total number of shares in the company for a total amount of not more than SEK 100,000,000 that Hoist Finance announced on 25 July 2024. The repurchase programme runs during the period from

Repurchases of shares by EQT AB during week 33, 2024

Between 12 August 2024 and 16 August 2024 EQT AB (LEI code 213800U7P9GOIRKCTB34) (“EQT”) has repurchased in total 371,231 own ordinary shares (ISIN: SE0012853455).The repurchases form part of the repurchase program of a maximum of 2,000,000 own ordinary shares for a total maximum amount of SEK 1,000,000,000 that EQT announced on 27 May 2024. The repurchase program, which runs between 19 July 2024 and 23 August 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052. EQT ordinary shares have been

There are no items matching the current filter
There are no more items matching the current filter
Back to top